Cognitive effects and antipsychotic treatment

Kasper, Siegfried; Resinger, E.

doi:10.1016/s0306-4530(02)00115-4

Cited by 62 publications

(24 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This issue requires further scrutiny. However, SGAs may allow for improvements to take place (due to practice or due to effects beyond practice), while FGAs may preclude such improvements at traditional dosage levels (eg by impairing cognitive and motor learning in the basal ganglia) or may even impede performance (by slowing motor functioning or by requiring anticholinergic medication to control EPMS) (CWGoCTE, 1998;Kasper and Resinger, 2003;Carpenter and Gold, 2002). Interestingly, low-dose haloperidol (5 mg average daily dose) was found to result in similar cognitive improvements in schizophrenic patients as risperidone (6 mg average daily dose) over 2 years (Green et al, 2002), implying that even FGAs may have neurocognitive benefits at lower than traditional doses.…”

Section: Cognitive Improvement In Schizophrenic Patientsmentioning

confidence: 99%

Cognitive Improvement in Schizophrenic Patients does not Require a Serotonergic Mechanism: Randomized Controlled Trial of Olanzapine vs Amisulpride

Wagner

Quednow

Westheide

et al. 2004

Neuropsychopharmacol

View full text Add to dashboard Cite

Combined serotonin-2A (5-HT 2A ) and dopamine-2 (D 2 ) receptor blockade has been proposed as a candidate mechanism by which second-generation antipsychotics (SGAs) improve both cognition and negative symptoms in schizophrenic patients, in contrast to antipsychotics of the first generation. The SGA amisulpride, however, only binds to D 2 /D 3 receptors, which makes it an interesting tool to test this assumption. In a randomized controlled trial, 52 schizophrenic patients were allocated to treatment with either olanzapine (10-20 mg/day) or amisulpride (400-800 mg/day). A comprehensive neuropsychological test battery and clinical ratings were used to assess participants at inclusion and after 4 and 8 weeks. Cognitive improvements of moderate size were observed, with effect sizes similar to those obtained in previous studies on the cognitive effects of SGAs. Importantly, amisulpride was not inferior to olanzapine for any cognitive domain. Combined 5-HT 2A /D 2 receptor blockade is probably not necessary for cognitive improvement by SGAs.

show abstract

Section: Cognitive Improvement In Schizophrenic Patientsmentioning

confidence: 99%

Cognitive Improvement in Schizophrenic Patients does not Require a Serotonergic Mechanism: Randomized Controlled Trial of Olanzapine vs Amisulpride

Wagner

Quednow

Westheide

et al. 2004

Neuropsychopharmacol

View full text Add to dashboard Cite

show abstract

“…However, we are reminded again that improvement in selective outcome measures is not necessarily the same as identifying predictors or even markers of overall response. One study did indicate semantic fluency and orthographic fluency to be significant predictors of clozapine response, with an overall accuracy of 88% in predicting responder status (Stip et al 1999), a finding in keeping with a number of overviews identifying improvement in verbal fluency with clozapine (McGurk 1999;Meltzer et al 1999;Perez-Gomez and Junque 1999;Kasper and Resinger 2003). It has been found in another investigation, though, that verbal fluency improved in both responders and nonresponders (Hagger et al 1993), and it is of note that improvement in this domain, as well as other cognitive measures, has been noted with other antipsychotics as well Kasper and Resinger 2003).…”

Section: Cognitive/neuropsychologicalmentioning

confidence: 65%

Predictors and markers of clozapine response

Chung

Remington

2005

Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…The second hypothesis has to do with practice and learning effects. Some authors have reported that patients receiving atypical antipsychotics show more practice effects on neuropsychological tests than do those treated with traditional drugs 47 , and therefore this type of effect would be more clearly observed on tests of learning.…”

Section: Main Findingsmentioning

confidence: 99%

Antipsychotic effects on cognition in schizophrenia: A meta-analysis of randomised controlled trials

et al. 2009

View full text Add to dashboard Cite

-Background and Objectives: Several studies have shown an improved performance on neuropsychological tests among patients treated with atypical antipsychotics compared to traditional ones. Here we present a meta-analysis of various randomised control trials with the aim of exploring whether patients treated with atypical agents obtain better results than those treated with traditional ones.Methods: The studies to be included were located electronically in November 2008 via the Medline database. A systematic review and a meta-analysis were undertaken; effect sizes were combined according to the random effects model. The effects of several moderating variables were evaluated.Results: The results, based on 18 independent studies (N = 1808), indicate that in terms of the global cognitive index atypical antipsychotics offer minor benefits compared to typical agents as regards the cognitive function of patients, the mean effect size being 0.17 (95% CI 0.04 -0.29). This observed effect was similar across the studies despite differences in their quality, the dose of haloperidol, the duration of treatment, pharmaceutical industry support, or the atypical antipsychotic used (all p > 0.05).Conclusions: The results suggest that compared to typical antipsychotics, atypical drugs produce a slight improvement in the global cognitive index, and several cognitive domains show a slight improvement in the neuropsychological performance of patients. We encourage further research on the relative effectiveness of several atypical antipsychotics.

show abstract

Cognitive effects and antipsychotic treatment

Cited by 62 publications

References 40 publications

Cognitive Improvement in Schizophrenic Patients does not Require a Serotonergic Mechanism: Randomized Controlled Trial of Olanzapine vs Amisulpride

Cognitive Improvement in Schizophrenic Patients does not Require a Serotonergic Mechanism: Randomized Controlled Trial of Olanzapine vs Amisulpride

Predictors and markers of clozapine response

Antipsychotic effects on cognition in schizophrenia: A meta-analysis of randomised controlled trials

Contact Info

Product

Resources

About